Heritability and family-based GWAS analyses of the
*N*-acyl ethanolamine and ceramide lipidome

reveal genetic influence over circulating lipids

Kathryn A. McGurk,1,2,* Simon G. Williams,1 Hui Guo,3 Hugh Watkins,4,5 Martin
Farrall,4,5 Heather J. Cordell,6 Anna Nicolaou,2,8 Bernard D. Keavney1,7,8,**

1Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health,
Manchester Academic Health Science Centre, University of Manchester, Manchester,
UK
2Laboratory for Lipidomics and Lipid Biology, Division of Pharmacy and Optometry,
Faculty of Biology, Medicine and Health, Manchester Academic Health Science
Centre, University of Manchester, Manchester, UK.
3Division of Population Health, Health Services Research & Primary Care, Faculty of
Biology, Medicine and Health, Manchester Academic Health Science Centre,
University of Manchester, UK
4Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University
of Oxford, Oxford, UK
5Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
6Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
7Manchester Heart Centre, Manchester University NHS Foundation Trust, UK
8These authors contributed equally to this work

Email addresses:

Kathryn A. McGurk: Kathryn.McGurk@manchester.ac.uk
Simon G. Williams: simon.williams2@manchester.ac.uk
Hui Guo: hui.guo@manchester.ac.uk
Hugh Watkins: hugh.watkins@rdm.ox.ac.uk
Martin Farrall: mfarrall@well.ox.ac.uk
Heather J. Cordell: heather.cordell@newcastle.ac.uk
Anna Nicolaou: Anna.Nicolaou@manchester.ac.uk
Bernard D. Keavney: Bernard.Keavney@manchester.ac.uk

Correspondence:

*kathryn.mcgurk@manchester.ac.uk @KathrynMcGurk
**bernard.keavney@manchester.ac.uk @KeavneyLab
Abstract

Certain signalling lipids of the $N$-acyl ethanolamine (NAE) and ceramide (CER) classes are emerging as novel biomarkers of cardiovascular disease. We sought to establish the heritability of plasma NAEs (including endocannabinoid anandamide) and CERs, and identify common DNA variants influencing the circulating concentrations of the heritable lipid species. Eleven NAEs and thirty CERs were analysed in plasma samples from 999 members of 196 British Caucasian families, using targeted mass spectrometry-based lipidomics (UPLC-MS/MS). Family-based heritability was estimated and GWAS analyses were undertaken. All lipids were significantly heritable over a wide range ($h^2 = 18\%-87\%$). A missense variant (rs324420) in the gene encoding the enzyme fatty acid amide hydrolase ($FAAH$), which degrades NAEs, associated at GWAS significance ($P<5\times10^{-8}$) with four NAEs (DHEA, PEA, LEA, VEA). This SNP, previously reported to be associated with addictive behaviour, was associated with an approximately 10% per-allele difference in mean plasma NAE species. Additionally, we have extended the previously described association between rs680379 in the gene encoding the rate limiting step of CER biosynthesis ($SPTLC3$) and CERs to a wider range of species (e.g. CER[N(24)S(19)] and rs680379 ($P = 4.82\times10^{-27}$)). We have shown three novel associations ($CD83$, $SGPP1$, $FBXO28-DEGS1$) influencing plasma CER traits, two of which ($SGPP1$ and $DEGS1$) implicate CER species in haematological phenotypes. This first genetic analysis of plasma NAE species, and a wide range of CER mediators, highlights these bioactive lipids as substantially heritable and influenced by SNPs in key metabolic enzymes.
Introduction

Genetic studies in large numbers of individuals have identified loci where common genetic variation influences the prevalence of the major plasma lipid species, such as HDL- and LDL-cholesterol, and triglycerides\(^1,2\). Although lipids are not DNA-encoded, their activities and metabolism are strongly controlled by DNA-encoded enzymes and other proteins. Recent advances in targeted bioanalytics have enabled quantitative analyses of a greater proportion of the mediator lipidome in blood, supporting attempts to identify genetic associations for low-concentration bioactive lipid species to potentially find disease biomarkers.

Bioactive lipids of the \(N\)-acyl ethanolamine (NAE) and ceramide (CER) classes have potent roles in inflammation and immunity\(^3\)\(^-\)\(^5\). NAEs are fatty acid derivatives, derived from membrane phospholipids and degraded by the enzyme fatty acid amide hydrolase (\(FAAH\); Figure 1A). This class of bioactive lipids includes the endocannabinoid anandamide (AEA), the nuclear factor agonist palmitoyl ethanolamide (PEA) and a number of other species with roles in neuronal signalling, pain and obesity\(^6\)\(^-\)\(^9\). The contribution of genetic factors to the variation in NAEs has not yet been studied.

Ceramides are derivatives of sphingoid bases (e.g. sphingosine and dihydrosphingosine) and fatty acids (Figure 1B). The first and rate limiting step\(^10\) of the \textit{de novo} biosynthesis is catalysed by the enzyme serine palmitoyltransferase, a heterodimeric protein whose monomers are encoded by the \textit{SPTLC1-3} genes. CER play important roles in apoptosis\(^11\). Recently, some circulating CER derivatives of 18-
carbon sphingosine and non-hydroxy fatty acids (e.g. CER[N(16)S(18)]) have been identified as novel biomarkers of cardiovascular death\textsuperscript{12}, type-2 diabetes, and insulin resistance\textsuperscript{13}. However, the contribution of genetic factors to the circulating levels of CER has only been investigated for six species, namely: CER[N(16)S(18)], CER[N(20)S(18)], CER[N(22)S(18)], CER[N(23)S(18)], CER[N(24)S(18)], and CER[N(24:1)S(18)], found in plasma and serum via untargeted shotgun lipidomics\textsuperscript{14,15}.

In this study we investigate the role of genetics in determining plasma levels of 11 NAE and 30 CER species, in 196 British Caucasian families comprising 999 individuals. Using targeted, quantitative lipidomics, we show for the first time that these bioactive lipid mediators are substantially heritable, and demonstrate that plasma NAEs and a wide range of CERs are influenced by SNPs in key metabolic enzymes (\textit{FAAH, SPTLC3, DEGS1, SGPP1}). Furthermore, we identify a novel inflammatory locus (\textit{CD83}) associated with CER species, and implicate CERs in haematological phenotypes through \textit{DEGS1} and \textit{SGPP1}.
Subjects and Methods

Family recruitment

Families were recruited for a quantitative genetic study of hypertension and other cardiovascular risk factors, and selected via a proband with essential hypertension (secondary hypertension was excluded using standard clinical criteria)\(^{16}\). Probands were recruited from outpatients attending the John Radcliffe Hospital, Oxford hypertension clinic, or via their family doctors. Included family members were U.K. residents of self-reported European ancestry and were required to consist of 3 or more siblings quantitatively assessable for blood pressure if one parent of the sibship was available for blood sampling, or 4 or more siblings if no parent was available. First, second and third degree relatives were then recruited to assemble a series of extended families. The collection protocol obtained ethical clearance from the Central Oxford Research Ethics Committee (06/Q1605/113) and it corresponds with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.

This cohort of extended families has previously been shown to have adequate power to detect moderate-sized genetic influences on quantitative traits\(^{17,18}\). The participants were fully phenotyped for cardiovascular risk factors, blood biochemical measures, and anthropometric traits. Non-fasting blood samples were collected, plasma separated, and stored at -80°C. DNA was extracted from whole blood by standard methods.
UPLC/ESI-MS/MS mediator lipidomics

Plasma samples were extracted and analysed by mass spectrometry as previously described\(^{19,20}\). Briefly, lipids were extracted from plasma (1 mL) using chloroform-methanol in the presence of class specific internal standards: C17S, C17DS, and CER[N(25)S(18)] (50 pmol/sample; Ceramide/Sphingoid Internal Standard Mixture I, Avanti Polar Lipids, USA) for CER, and AEA-\(d_8\) (20 ng/sample; Cayman Chemical Co., USA) for NAE. Targeted lipidomics was performed on a triple quadrupole mass spectrometer (Xevo TQS, Waters, UK) with an electrospray ionisation probe coupled to a UPLC pump (Acquity UPLC, Waters, UK). CER species were separated on a C8 column (2.1 x 100 mm) and NAE were separated on a C18 column (2.1 x 50 mm) (both Acquity UPLC BEH, 1.7\(\mu\)m, Waters, UK). NAE species were quantified using calibration lines of synthetic standards (Cayman Chemical); relative quantitation of CER was based on class specific internals standards (Avanti Polar Lipids). Pooled plasma samples from healthy volunteers were used to create quality control samples that were extracted and analysed blindly alongside the familial samples.

Statistical analysis

Covariate adjustment

Systematic error was considered from a variety of sources and assessed for collinearity; mass spectrometry batch and a trait created to adjust for sample abnormality (haemolysis or presence of white blood cells; present in 14% of samples) were included as potential covariates. Ascertainment selection was modelled via binary hypertension status. The resulting concentrations for each lipid species from the pooled quality control samples were used for adjustment of systematic errors during extraction, quantitation, and data processing. The final set of potential
covariates included mass spectrometry batch, sample abnormality, quality control sample measures, age, age^2, sex, hypertension status, BMI, and total cholesterol. The lipid measurements were assessed for effect of potential covariates using stepwise multiple linear regression to identify the best set of predictors, using the ‘caret’ package and ‘leapSeq’ method in R (version 3.5.2) (see Table S1 for predictors). Multiple linear regression of the best predictors was undertaken using the ‘lm’ function in R. Residuals from the covariate-adjusted regression models were standardized to have a mean of 0 and a variance of 1. Outliers were assessed using the R package ‘car’, assessing each observation by testing them as a mean-shift outlier based on studentized residuals, to remove the most extreme observations (Bonferroni P-value of P<0.05). Missing values were coded as such in the genetics analyses. As lipid mediators can exert individual bioactivities, all lipid species were treated uniquely for all analyses, intra-class correlation analyses are depicted in Figure S1.

**Genome-wide genotyping quality control**

Genotyping was performed using the Illumina 660W-Quad chip on 1,234 individuals (580 males and 654 females) including 248 founders, at 557,124 SNPs. Quality control of the genotyping data was undertaken using PLINK^21 (version 1.9). No duplicate variants were found. SNPs that were identified as Mendelian inconsistencies (--mendel-multigen) were marked as missing. Gender checks assessed by F-statistic (--check-sex) showed that gender as inferred from 538,771 chromosomal SNPs agreed with reported status. SNPs with low genotyping rates (--geno 0.05), low minor allele frequency (--maf 0.01), and those that failed checks of Hardy-Weinberg Equilibrium (--hwe 1e-8) were excluded. Individuals with low genotype rates (--mind 0.05) and outlying heterozygosity were removed (0.31 - 0.33 included). Relatedness
was assessed by high levels of IBD sharing (--genome and --rel-check) and by visualisation of pairs of individuals' degree of relatedness (through plotting the proportion of loci where the pair shares one allele IBD (Z1) by the proportion of loci where the pair shares zero alleles IBD (Z0)), and two outlier individuals were removed. Ethnicity was assessed via principal components analysis with genotype data from the 1,000 Genome Project\textsuperscript{22}, which confirmed all participants were of European/CEU origin. Following quality control, 503,221 autosomal SNPs from 1,219 individuals (216 families) were available for SNP-based heritability assessments, of which 999 individuals (196 families; 198 founders and 801 non-founders) had plasma available for lipidomics.

\textit{Heritability estimates}

SNP-based heritability was estimated using GCTA software (version 1.26.0)\textsuperscript{23,24}. A genetic relationship matrix was created from the quality controlled genotyping data and the --reml command was used to estimate variance of the traits explained by the genotyped SNPs. A complementary estimation of pedigree-based heritability was undertaken using the QTDT software (version 2.6.1)\textsuperscript{25}, by specifying the -we and -veg options to compare an environmental only variance model with a polygenic and environmental variances model. The P-values presented are adjusted for 30 tests (CER) or 11 tests (NAE) via Bonferroni correction. The least significant adjusted P-value from the groups of lipid species described are depicted as $P_{\text{adj}}<X$.

\textit{Genotyping imputation}

Following genotyping quality control, 503,221 autosomal SNPs were available to inform imputation. Imputation was performed through the Michigan Imputation
Server (version v1.0.4)\(^{26}\), specifying pre-phasing with Eagle\(^{27}\) (version 2.3) and imputation by Minimac\(^{26}\) using the European population of the Human Reference Consortium\(^{28}\) (version hrc.r1.1.2016). Following imputation, duplicate SNPs and SNPs with \(r^2<0.8\) were removed to generate a final set of 10,652,600 SNPs. Quality control was undertaken for the imputed data on the 999 individuals with lipidomics available, as follows: SNPs that were identified as Mendelian inconsistencies (\(-\)mendel-multigen) were marked as missing. SNPs with low call rates (\(-\)geno 0.05), low minor allele frequency (\(-\)maf 0.05), and those that failed checks of Hardy-Weinberg Equilibrium (\(-\)hwe 1e-8) were excluded, resulting in a final count of 5,280,459 SNPs available for genome-wide association analyses.

**Family-based genome-wide association studies**

Linear mixed modelling approaches were used to account for family structure. Family-based genome-wide association analyses were undertaken for each lipid trait using GCTA software (version 1.26.0), specifying mixed linear model association analyses (\(-\)mlma). Genomic control inflation factors from the GWAS analyses can be found in Table S2. The least significant P-values of the significantly associated SNPs (\(P<5\times10^{-8}\)) are depicted as \(P<X\) in the manuscript. Significantly associated SNPs were analysed by Ensembl API Client (version 1.1.5 on GRCh37.p13) to identify neighbouring genes. Further analyses were undertaken of the significantly associated SNPs; expression quantitative trait loci (eQTL) were identified using the GTEx portal browser (version 8), assessment of previously identified SNPs from GWAS was undertaken using the GWAS Catalog, and assessment of PheWAS with the UK Biobank\(^{29}\) was undertaken using the Gene Atlas Browser (see Web Resources).
Two-sample Mendelian randomisation analysis

Two sample Mendelian randomisation (2SMR) analysis was undertaken in R following the guidelines provided by Davey Smith et al [https://mrcieu.github.io/TwoSampleMR/]30. Briefly, selected examples of the significant associations identified for each class of lipid were analysed by 2SMR for a number of previously published GWAS of interest. The GWAS significant associations (P<5x10⁻⁸) identified for NAE species PEA, and CER traits CER[N(22)S(19)], CER[N(24)S(16)], and CER[N(24)S(19)]/CER[N(24)DS(19)] ratio, were assessed for coronary artery disease (all), addiction (PEA), Type-2 Diabetes (CER[N(22)S(19)]), and blood cell counts (CER[N(24)S(16)] and CER[N(24)S(19)]/CER[N(24)DS(19)] ratio). Details on the published GWAS used as outcomes are presented in Table S3. As many GWAS associated SNPs were in linkage disequilibrium, the following SNPs remained in the analysis after the data clumping step; rs324420 (FAAH; PEA), rs438568 (SPTLC3; CER[N(22)S(19)]), rs7160525 (SGPP1; CER[N(24)S(16)]), and rs4653568 (DEGS1; CER[N(24)S(19)]/CER[N(24)DS(19)] ratio).
Results

Population characteristics
Plasma samples of 999 participants from 196 British Caucasian families were included in the genetic analyses. The families consisted of 1-24 members (mean of 5 members) with plasma available for lipidomics analyses (Figure S2). Participant descriptions are listed in Table 1.

Lipidomics descriptive statistics
Of the 11 NAE species identified in plasma, palmitoyl ethanolamide (PEA) was at highest abundance (1.89 ± 1.36 ng/ml (mean ± SD)), and of the 30 plasma CER species, CER[N(24)S(18)] was most abundant (128.87 ± 61.00 pmol/ml). In some cases, the ratio of product/precursor metabolites involved in specific enzymatic reactions was measured; this allowed for examination of the genetic variants in corresponding enzymes (e.g. the ratio CER[NS] to CER[NDS] is indicative of DEGS1 activity, Figure 1B). Structure-based summations of total abundance and ratios that have previously been associated in the literature with cardiovascular risk \(^{12}\) were also assessed for genetic associations. A list of the species and measurements studied, and summary statistics are presented in Table S4.

Signalling lipid species are highly heritable
The NAE species had estimated heritabilities ranging from 45% to 82% (\(P_{adj}<6.72\times10^{-15}\)), with pentadecanoyl ethanolamide (PDEA) having the highest estimated heritability. Ceramide species showed a wide range in estimated heritability. Of the CER classes examined, CER[NS] species had heritabilities between 18% - 62% (\(P_{adj}<4.50\times10^{-7}\)), CER[NDS] species had estimated heritability of
32% - 52%, (P adj<3.00x10^{-11}), while CER[AS], sphingosine-1-phosphate (C18S1P), sphingosine (C18S) and dihydrosphingosine (C18DS) were all significantly heritable. Heritability results are depicted in Figure 2 (a detailed list is provided in Table S5). 

**Genome-wide association study of N-acyl ethanolamines**

There were conventionally GWAS significant (P<5x10^{-8}) associations between four NAEs (N-docosahexaenoic ethanolamide, DHEA; N-linoleoyl ethanolamide, LEA; N-palmitoyl ethanolamide PEA; vaccinoyl ethanolamide, VEA), as well as the sum of all NAEs (sumEA), with SNPs in the gene encoding fatty acid amide hydrolase (FAAH; Figure 3, with details in Table S6), which catalyses the degradation of NAEs (Figure 1A). The leading SNP is a missense variant (rs324420; C385A; P129T) and eQTL of FAAH in multiple tissues including whole blood. Presence of the missense variant causes the enzyme to display normal catalytic properties but decreased cellular stability\(^\text{31}\) by enhanced sensitivity of the enzyme to proteolytic degradation\(^\text{32}\). The magnitude of the genetic effect was considerable; for example, participants with the AA genotype of the lead SNP rs324420 had 22% increased mean plasma concentration of PEA (2.19 ± 1.57 ng/ml, n=51) compared to those carrying the CC genotype (1.79 ± 1.29 ng/ml, n=639). A LocusZoom plot of the association with the lipid PEA is depicted in Figure 4, with the 22-chromosome Manhattan plot depicted in Figure S3.

**Genome-wide association study of ceramides and related sphingolipids**

Seven CER[NS] and two CER[NDS] species were significantly associated with SNPs in an intergenic region on chromosome 20 (Figure 5, with example Manhattan plot depicted in Figure S4, and further details in Table S7). Assessing the SNPs using
GTEx confirmed them as liver eQTLs (Table S8) found 20,000 bases downstream of the gene encoding the third subunit of serine palmitoyltransferase (SPTLC3; Figure 6), which catalyses the rate-limiting step\(^{10}\) of CER biosynthesis (Figure 1B). The SNPs are associated with differences in the expression of the SPTLC3 gene in the liver, leading to changes in CER production that are reflected in altered plasma levels. Associated SNPs had considerable phenotypic effects, for example the AA genotype of the SNP rs680379 was associated with a 48% increase in the concentration of CER[N(24)S(19)] compared with the GG genotype (62.84 ± 24.86 pmol/ml [n=148], and 42.44 ± 18.48 pmol/ml [n=409], respectively). Furthermore, the summed total of all CER species with 24-carbon non-hydroxy fatty acids, and, independently, those with 19- and 20-carbon sphingosine bases, were found associated with the same SNPs at the SPTLC3 locus (Table S8). A novel association was identified for CER[N(26)S(19)] at a locus on chromosome 6, upstream to the gene for inflammatory protein CD83 (e.g. rs6940658, P=2.07x10\(^{-8}\); depicted in Figure S5 with further details in Table S7).

Association of ceramides and related traits with hematological phenotypes

The Gene Atlas Browser of PheWAS in the UK Biobank study was used to assess the association of significant SNPs identified here with the extensive number of phenotypes measured for the UK Biobank cohort. The ratio of CER[NS] to their precursor CER[NDS], is indicative of delta 4-desaturase, sphingolipid 1 (DEGS1) activity (Figure 1B). A set of SNPs in the upstream region of the DEGS1 gene on chromosome 1 associated with the product/precursor ratio, CER[N(24)S(19)]/CER[N(24)DS(19)] (P=4.34x10\(^{-8}\); depicted in Figure S6 with further details in Table S7). All significant SNPs were confirmed eQTLs of DEGS1 in
whole blood (Table S8). This locus associated with numerous blood cell phenotypes in the UKBiobank data (e.g. rs4653568 and mean platelet (thrombocyte) volume; P=4.77x10^{-12}; Table S8). A further set of SNPs upstream of the gene encoding sphingosine-1 phosphate phosphatase (SGPP1) were associated with CER[N(24)S(16)] (e.g. rs7160525, P=5.67x10^{-10}; Figure S7). This enzyme is involved in the recycling of CER[NS] species from sphingosine-1-phosphate and ceramide-1-phosphate (C1P) (Figure 1B). All significant SNPs at this locus were also associated with blood cell phenotypes, identified in the UK Biobank data (e.g. rs7160525 and mean platelet (thrombocyte) volume, P=3.28x10^{-29}; Table S8). The significant SNPs identified at both SGPP1 and DEGS1 were assessed by 2SMR using published blood cell count GWAS as outcome variables. The SNPs at both loci were found significant using 2SMR (P<0.05) in influencing platelet, red blood cell, and white blood cell traits. Table S9 describes the results in detail.

No significant GWAS associations were found with the particular CER species that have been previously investigated as biomarkers of coronary artery disease and type-2 diabetes (e.g. CER[N(16)S(18)]). The SPTLC3 locus has associated with these CERS previously. Therefore, an example CER (CER[N(22)S(19)]) which associated at GWAS significantly with the SPTLC3 locus was used to investigate the causality via two-sample Mendelian randomisation between the identified SNPs in SPTLC3 with coronary artery disease and type-2 diabetes. There was no significant association between the SPTLC3 locus and the cardiovascular disease endpoints (Table S9).
We show, for the first time, the substantial variation in heritability estimated for an array of signalling lipid mediators found in plasma, including low concentration members of the NAE and CER classes, and we identify GWAS significant associations between lipids and variants of the enzymes in their respective metabolic pathways. We have provided the first GWAS significant evidence of association between SNPs in the FAAH gene and plasma NAEs. Additionally, we have extended the previously described association between SNPs in the SPTLC3 gene and plasma CERs to a wider range of species. Our results indicate that these two genes are the major loci influencing plasma levels of NAEs and CERs, respectively. In addition, we have shown novel SNP associations (CD83, SGPP1, FBXO28-DEGS1) influencing plasma CER species.

Genetic analyses of N-acyl ethanolamine species

We show for the first time associations at GWAS significance for NAE species (DHEA, LEA, PEA, and VEA) with a missense change in the NAE degradation enzyme FAAH. The association with PEA was identified previously in a single candidate gene study of mutations in FAAH in 114 subjects, which reported the same direction of effect on plasma AEA, PEA, STEA and OEA species but with P-values insignificant at genome-wide levels (0.003<P<0.04). Here, in this study of 999 related participants, we identified additional NAE species significantly associated with the SNP (DHEA, LEA, and VEA), though we did not find significant association at the locus for AEA, STEA or OEA species. We observed a similar trend to the previous paper when comparing the plasma levels of NAE species between
participants with the missense AA genotype, and those with the wildtype CC genotype (Figure S8).

While the FAAH missense SNP rs324420 is not associated with any disease endpoints identified from GWAS to date, the A allele, associated with higher NAE levels, has been reported to increase the risk of polysubstance addiction and abuse [MIM: 606581] in three candidate gene studies totaling 863 cases and 2,170 controls\textsuperscript{32,34,35} and to potentially contribute to pain insensitivity\textsuperscript{36} [MIM: 618377], obesity\textsuperscript{37}, and anxiety\textsuperscript{38,39}. PheWAS analysis using the Gene Atlas UK Biobank online browser however did not identify significant association in a similar number of UK Biobank cases of substance abuse/dependency (OR for A allele = 1.10; $P = 0.14$; 746 cases and 451,518 controls) nor the further 2SMR analyses undertaken here using UK Biobank addiction treatment codes (18 cases, 462999 controls; Table S9). It is possible that misclassification bias has affected the UK Biobank PheWAS; among the 451,518 UK Biobank participants assigned as controls, some reported dependencies on other substances and behaviours, such as coffee, cigarettes, prescription drugs, and gambling. The potential implication of NAE species in addiction through the association with the FAAH SNP, warrants further investigation in larger numbers of cases.

As direct cannabinoid receptor 1 (CB1) antagonist drugs have caused severe adverse psychiatric effects\textsuperscript{40}, FAAH inhibitors are being evaluated as an alternative approach to modulating endocannabinoid signalling. However, in 2016, a FAAH inhibitor resulted in severe neurological side-effects in a Phase I trial, hypothesised due to off-target drug effects\textsuperscript{41}. As the functional FAAH SNP rs324420 did not associate with
any adverse phenotypes in the UK Biobank, it is likely that on-target effects of FAAH
inhibitor drugs do not have substantial risks of causing conditions that occurred with
appreciable frequency in UK Biobank.

Genetic analyses of ceramides and other sphingolipid species

Narrow-sense heritability has been estimated for six CER (CER[N(16)S(18)],
CER[N(18)S(18)], CER[N(20)S(18)], CER[N(22)S(18)], CER[N(24)S(18)],
CER[N(24:1)S(18)] and the corresponding dihydroceramide species
(CER[N(16)DS(18)], CER[N(18)DS(18)], CER[N(20)DS(18)], CER[N(22)DS(18)],
CER[N(24)DS(18)], CER[N(24:1)DS(18)], showing estimated heritability of 0.37 -
0.51 (P<0.01) for CER[NS] and 0.09 - 0.34 (P<0.01) for CER[NDS] in 42 Mexican
American families. Here, we show assessing a larger array of species, that further
CER[NS] and CER[NDS] were significantly heritable, expanding on these previous
estimates.

The rs7157785 variant in sphingosine 1-phosphate phosphatase 1 (SGPP1), a CER
metabolic enzyme, has been identified previously in GWAS of sphingomyelin, total cholesterol, glycerophospholipids, total cholesterol, and the ratio of an
unknown blood lipid (X-08402) to cholesterol. The novel association with
CER[N(24)S(16)] we describe is consistent with the gene’s role in influencing
CER[NS] production, through the formation of sphingosine (C18S) for CER[NS]
biosynthesis, and the production of CER[NS] from ceramide 1-phosphate (C1P)
(Figure 1). The other significant SNPs identified at the same locus which associated
with this CER species have been previously identified in further GWAS studies of
blood phospholipids, red cell distribution width, sphingomyelin, and unknown
blood metabolite X-1051045. All SNPs identified at this locus associated in the
UKBiobank PheWAS assessment, and 2SMR analyses, with multiple blood cell
counts and other hematological phenotypes (Table S8). Association with
hematological phenotypes was also identified for the locus on chromosome 1 at
DEGS1, found via the GWAS results analysing the ratio of CER[N(24)S(19)] to
CER[N(24)DS(19)]. CER have been previously shown to stimulate erythrocyte
formation through platelet activating factor48. However, further studies will be
required to identify the mechanism of the association between genetically determined
plasma ceramide levels and blood cell phenotypes.

CER[N(26)S(19)] associated at GWAS with SNPs at a novel locus on chromosome 6,
upstream to the gene encoding the inflammatory protein CD83 (P=2.07x10^{-8}), a
member of the immunoglobulin superfamily of membrane receptors expressed by
antigen-presenting white blood cells, leukocytes, and dendritic cells49. An interaction
between CD83 and CER is currently unknown, but given the involvement of ceramide
signalling in inflammation and immunity50,51, it would be of interest to investigate
further.

Association between some CER species and the SPTLC3 SNP rs680379 has been
identified previously through the use of shotgun lipidomics for five CER species
(CER[N(16)S(18)], CER[N(22)S(18)], CER[N(23)S(18)], CER[N(24)S(18)], and
CER[N(24:1)S(18)])14,15. Here, we identify associations between an additional seven
CER[NS] and two CER[NDS] plasma species and this SNP, and with other eQTLs of
serine palmitoyltransferase at the same locus; as this enzyme is the rate limiting step
for the de novo biosynthesis of CER, this association may have wider implications.
The information gathered from the eQTL analysis highlights all of the SPTLC3 confirmed eQTLs act in the liver, which is a major site for plasma CER biosynthesis. PheWAS analysis in UK Biobank, nor 2SMR analysis, did not identify significant disease associations with the SPTLC3 locus. A number of CER[NS] species have been studied as potential biomarkers of cardiovascular disease and diabetes\textsuperscript{12,52}. While GWAS significant associations were not found with these lipids, the extent to which specific species have a role in cardiovascular disease remains debated\textsuperscript{53–60}.

The sample size analysed here (999 participants) is the largest study analysing this number of plasma NAE and CER species to date\textsuperscript{61}. However, it is still a modest study for GWAS analyses. The associations we have uncovered suggest that further investigation of heritable lipid species for which no GWAS association was found in this study would be of interest.
Supplemental Data

Supplemental Data include nine tables and eight figures.

Acknowledgements

We are very grateful to the families involved in this study. K.M. is supported by an MRC Doctoral Award (MR/K501311/1), the University of Manchester President’s Doctoral Scholarship, and Doctoral Academy Society Membership Fund. AN is supported in part by the NIHR Manchester Biomedical Research Centre. BK is supported by a BHF Personal Chair.

Declaration of interests

The authors declare no competing interests.

Web Resources

OMIM: http://www.omim.org/
GWAS Catalog: https://www.ebi.ac.uk/gwas/
GTEx Portal: https://gtexportal.org/
UCSC Genome Browser: https://genome.ucsc.edu/cgi-bin/hgGateway/
Gene Atlas UKBiobank Browser: http://geneatlas.roslin.ed.ac.uk/
UKBiobank Data Show case [April 2019]: http://biobank.ndph.ox.ac.uk/showcase/
LocusZoom: http://csg.sph.umich.edu/locuszoom/
References

1. Teslovich, T.M., Musunuru, K., Smith, A. V, Edmondson, A.C., Stylianou, I.M., Koseki, M., Pirruccello, J.P., Ripatti, S., Chasman, D.I., Willer, C.J., et al. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713.

2. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich, M.L., Mora, S., et al. (2013). Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1285.

3. MacEyka, M., and Spiegel, S. (2014). Sphingolipid metabolites in inflammatory disease. Nature 510, 58–67.

4. Kendall, A.C., and Nicolaou, A. (2013). Bioactive lipid mediators in skin inflammation and immunity. Prog. Lipid Res. 52, 141–164.

5. Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., et al. (2009). Activated endocannabinoid system in coronary artery disease and anti inflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119, 28–36.

6. Devane, W.A., Hanuš, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (80-. ). 258, 1946–1949.

7. Wilson, R.I., and Nicoll, R. a (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588–592.

8. Hohmann, A.G., Suplita, R.L., Bolton, N.M., Neely, M.H., Fegley, D., Mangieri, R., Krey, J.F., Michael Walker, J., Holmes, P. V., Crystal, J.D., et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108–1112.
9. Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F.C., Sharma, A.M., et al. (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54, 2838–2843.

10. Perry, D.K., Carton, J., Shah, A.K., Meredith, F., Uhlinger, D.J., and Hannun, Y.A. (2000). Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. 275, 9078–9084.

11. Perry, D.K., and Hannun, Y.A. (1998). The role of ceramide in cell signaling.

Biochim. Biophys. Acta 1436, 233–243.

12. Laaksonen, R., Ekroos, K., Sysi-Aho, M., Hilvo, M., Vihervaara, T., Kauhanen, D., Suoniemi, M., Hurme, R., März, W., Scharnagl, H., et al. (2016). Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J. 37, 1967–1976.

13. Haus, J.M., Kashyap, S.R., Kasumov, T., Zhang, R., Kelly, K.R., Defronzo, R.A., and Kirwan, J.P. (2009). Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58, 337–343.

14. Hicks, A.A., Pramstaller, P.P., Johansson, A., Vitart, V., Rudan, I., Ugocsai, P., Aulchenko, Y., Franklin, C.S., Liebisch, G., Erdmann, J., et al. (2009). Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet. 5, e1000672.

15. Demirkan, A., van Duijn, C.M., Ugocsai, P., Isaacs, A., Pramstaller, P.P., Liebisch, G., Wilson, J.F., Johansson, Â., Rudan, I., Aulchenko, Y.S., et al. (2012). Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations. PLoS Genet. 8, e1002490.

16. Keavney, B., Mayosi, B., Gaukrodger, N., Imrie, H., Baker, M., Fraser, R., Ingram, M., Watkins, H., Farrall, M., Davies, E., et al. (2005). Genetic variation at the
locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. J. Clin. Endocrinol. Metab. 90, 1072–1077.

17. Baker, M., Rahman, T., Hall, D., Avery, P.J., Mayosi, B.M., Connell, J.M.C., Farrall, M., Watkins, H., and Keavney, B. (2007). The C-532T polymorphism of the angiotensinogen gene is associated with pulse pressure: A possible explanation for heterogeneity in genetic association studies of AGT and hypertension. Int. J. Epidemiol. 36, 1356–1362.

18. Vickers, M.A., Green, F.R., Terry, C., Mayosi, B.M., Julier, C., Lathrop, M., Ratcliffe, P.J., Watkins, H.C., and Keavney, B. (2002). Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc. Res. 53, 1029–1034.

19. Kendall, A.C., Pilkington, S.M., Massey, K. a, Sassano, G., Rhodes, L.E., and Nicolaou, A. (2015). Distribution of Bioactive Lipid Mediators in Human Skin. J. Invest. Dermatol. 135, 1510–1520.

20. Cucchi, D., Camacho-Muñoz, D., Certo, M., Niven, J., Smith, J., Nicolaou, A., and Mauro, C. (2019). Omega-3 polyunsaturated fatty acids impinge on CD4+ T cell motility and adipose tissue distribution via direct and lipid mediator-dependent effects. Cardiovasc. Res. cvz208.

21. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D., Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J., et al. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575.

22. Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Bentley, D.R., Chakravarti, A., Clark, A.G., Donnelly, P., Eichler, E.E., Fliceck, P., et al. (2015). A
24. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders, A.K., Nyholt, D.R., Madden, P.A., Heath, A.C., Martin, N.G., Montgomery, G.W., et al. (2010). Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565–569.

25. Zaitlen, N., Kraft, P., Patterson, N., Pasaniuc, B., Bhatia, G., Pollack, S., and Price, A.L. (2013). Using Extended Genealogy to Estimate Components of Heritability for 23 Quantitative and Dichotomous Traits. PLoS Genet. 9, e1003520.

26. Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy, S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284–1287.

27. Loh, P.R., Danecek, P., Palamara, P.F., Fuchsberger, C., Reshef, Y.A., Finucane, H.K., Schoenherr, S., Forer, L., McCarthy, S., Abecasis, G.R., et al. (2016). Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 48, 1443–1448.

28. McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang, H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283.

29. Sudlow, C., Gallacher, J., Green, J., Sprosen, T., Pell, J., Burton, P., Matthews, P., Liu, B., Danesh, J., Downey, P., et al. (2015). UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old Age. PLOS Med. 12, e1001779.
30. Smith, G.D., and Hemani, G. (2014). Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89–R98.

31. Chiang, K.P., Gerber, A.L., Sipe, J.C., and Cravatt, B.F. (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 13, 2113–2119.

32. Sipe, J.C., Chiang, K., Gerber, A.L., Beutler, E., and Cravatt, B.F. (2002). A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl. Acad. Sci. 99, 8394–8399.

33. Sipe, J.C., Scott, T.M., Murray, S., Harismendy, O., Simon, G.M., Cravatt, B.F., and Waalen, J. (2010). Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 5, 1–6.

34. Flanagan, J.M., Gerber, A.L., Cadet, J.L., Beutler, E., and Sipe, J.C. (2006). The fatty acid amide hydrolase 385 A/A (P129T) variant: Haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum. Genet. 120, 581–588.

35. Sim, M.S., Hatim, A., Reynolds, G.P., and Mohamed, Z. (2013). Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. Pharmacogenomics 14, 505–514.

36. Cajanus, K., Holmström, E.J., Wessman, M., Anttila, V., Kaunisto, M.A., and Kalso, E. (2016). Effect of endocannabinoid degradation on pain: role of FAAH polymorphisms in experimental and postoperative pain in women treated for breast cancer. Pain 157, 361–369.

37. Sipe, J.C., Waalen, J., Gerber, A., and Beutler, E. (2005). Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int.
38. Dincheva, I., Drysdale, A.T., Hartley, C.A., Johnson, D.C., Jing, D., King, E.C., Ra, S., Gray, J.M., Yang, R., DeGruccio, A.M., et al. (2015). FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat. Commun. 6, 1–9.

39. Lazary, J., Eszlarí, N., Juhasz, G., and Bagdy, G. (2016). Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma. Eur. Neuropsychopharmacol. 26, 1020–1028.

40. Mach, F., Montecucco, F., and Steffens, S. (2009). Effect of blockage of the endocannabinoid system by CB1 antagonism on cardiovascular risk. Pharmacol. Reports 61, 13–21.

41. Mallet, C., Dubray, C., and Dualé, C. (2016). FAAH inhibitors in the limelight, but regrettably. Int. J. Clin. Pharmacol. Ther. 54, 498–501.

42. Bellis, C., Kulkarni, H., Mamtani, M., Kent, J.W., Wong, G., Weir, J.M., Barlow, C.K., Diego, V., Almeida, M., Dyer, T.D., et al. (2014). Human plasma lipidome is pleiotropically associated with cardiovascular risk factors and death. Circ. Cardiovasc. Genet. 7, 854–863.

43. Draisma, H.H.M., Pool, R., Kobl, M., Jansen, R., Petersen, A.-K., Vaarhorst, A.A.M., Yet, I., Haller, T., Demirkan, A., Esko, T., et al. (2015). Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels. Nat. Commun. 6, 7208.

44. Klarin, D., Damrauer, S.M., Cho, K., Sun, Y. V., Teslovich, T.M., Honerlaw, J., Gagnon, D.R., DuVall, S.L., Li, J., Peloso, G.M., et al. (2018). Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat. Genet. 50, 1514–1523.
45. Shin, S.Y., Fauman, E.B., Petersen, A.K., Krumsieck, J., Santos, R., Huang, J., Arnold, M., Erte, I., For forgetta, V., Yang, T.P., et al. (2014). An atlas of genetic influences on human blood metabolites. Nat. Genet. 46, 543–550.

46. Li, Y., Sekula, P., Wuttke, M., Wahrheit, J., Hausknecht, B., Schultheiss, U.T., Gronwald, W., Schlosser, P., Tucci, S., Ekici, A.B., et al. (2018). Genome-wide association studies of metabolites in patients with CKD identify multiple loci and illuminate tubular transport mechanisms. J. Am. Soc. Nephrol. 29, 1513–1524.

47. Astle, W.J., Elding, H., Jiang, T., Allen, D., Ruklisa, D., Mann, A.L., Mead, D., Bouman, H., Riveros-Mckay, F., Kostadima, M.A., et al. (2016). The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell 167, 1415–1429.

48. Lang, P.A., Kempe, D.S., Tanneur, V., Eisele, K., Klarl, B.A., Myssina, S., Jendrossek, V., Ishii, S., Shimizu, T., Waidmann, M., et al. (2005). Stimulation of erythrocyte ceramide formation by platelet-activating factor. J. Cell Sci. 118, 1233–1243.

49. Ju, X., Silveira, P.A., Hsu, W.-H., Elgundi, Z., Alingcastre, R., Verma, N.D., Fromm, P.D., Hsu, J.L., Bryant, C., Li, Z., et al. (2016). The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83 + -Activated T Cell Population. J. Immunol. 197, 4613–4625.

50. Maceyka, M., and Spiegel, S. (2014). Sphingolipid metabolites in inflammatory disease. Nature 510, 58–67.

51. Hannun, Y.A., and Obeid, L.M. (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139–150.

52. Hilvo, M., Salonurmi, T., Havulinna, A.S., Kauhanen, D., Pedersen, E.R., Tell, G.S., Meyer, K., Teeriniemi, A.M., Laatikainen, T., Jousilahti, P., et al. (2018).
Ceramide stearic to palmitic acid ratio predicts incident diabetes. Diabetologia 61, 1424–1434.

53. Wang, D.D., Toledo, E., Hruby, A., Rosner, B.A., Willett, W.C., Sun, Q., Razquin, C., Zheng, Y., Ruiz-Canela, M., Guasch-Ferré, M., et al. (2017). Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the PREDIMED trial. Circulation 135, 2028–2040.

54. Lopez, X., Goldfine, A.B., Holland, W.L., Gordillo, R., and Scherer, P.E. (2013). Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J. Pediatr. Endocrinol. Metab. 26, 995–998.

55. Jensen, P.N., Fretts, A.M., Yu, C., Hoofnagle, A.N., Umans, J.G., Howard, B. V., Sitlani, C.M., Siscovick, D.S., King, I.B., Sotoodehnia, N., et al. (2019). Circulating sphingolipids, fasting glucose, and impaired fasting glucose: The Strong Heart Family Study. EBioMedicine 41, 44–49.

56. Lemaitre, R.N., Yu, C., Hoofnagle, A., Hari, N., Jensen, P., Fretts, A.M., Umans, J.G., Howard, B. V., Sitlani, C.M., Siscovick, D.S., et al. (2018). Circulating sphingolipids, insulin, HOMA-IR and HOMA-B: The Strong Heart Family Study. Running title: Sphingolipids and insulin resistance markers. Diabetes 67, 1663–1672.

57. Yu, J., Pan, W., Shi, R., Yang, T., Li, Y., Yu, G., Bai, Y., Schuchman, E.H., He, X., and Zhang, G. (2015). Ceramide Is Upregulated and Associated With Mortality in Patients With Chronic Heart Failure. Can. J. Cardiol. 31, 357–363.

58. de Carvalho, L.P., Tan, S.H., Ow, G.S., Tang, Z., Ching, J., Kovalik, J.P., Poh, S.C., Chin, C.T., Richards, A.M., Martinez, E.C., et al. (2018). Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction. JACC Basic to Transl. Sci. 3, 163–175.

59. Pan, W., Yu, J., Shi, R., Yan, L., Yang, T., Li, Y., Zhang, Z., Yu, G., Bai, Y.,
Schuchman, E.H., et al. (2014). Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes. Coron. Artery Dis. 25, 230–235.

Bergman, B.C., Brozinick, J.T., Strauss, A., Bacon, S., Kerege, A., Bui, H.H., Sanders, P., Siddall, P., Kuo, M.S., and Perreault, L. (2015). Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am. J. Physiol. Endocrinol. Metab. 309, 398–408.

Hinterwirth, H., Stegemann, C., and Mayr, M. (2014). Lipidomics: Quest for molecular lipid biomarkers in cardiovascular disease. Circ. Cardiovasc. Genet. 7, 941–954.
Figure 1: Schematic overview of the biosynthetic pathways for (A) N-acyl ethanolamines and (B) ceramides

A) N-acyl ethanolamine species (NAE), including the endocannabinoid anandamide (AEA), are produced through four independent enzymatic pathways from the membrane phospholipid precursor (N-acyl phosphatidylethanolamine; NAPE). Fatty acid amide hydrolase (FAAH) degrades NAEs to free fatty acids (such as arachidonic acid for AEA) and ethanolamine. NAEs have signalling roles in pain, obesity, inflammation, and neurotransmission.

B) Ceramide (CER) species are biosynthesised via the enzyme serine palmitoyltransferase (SPTLC1-3) that converts palmitoyl-CoA and L-serine to 3-keto dihydrosphingosine, in the rate-limiting step of the sphingolipid de novo pathway. The resulting dihydrosphingosine (C18DS) is coupled to various fatty acids via ceramide synthases (CERS) to generate dihydroceramides [CER[NDS]] that are further converted to CER[NS] via the enzyme delta 4-desaturase (DEGS1). Conversion of these pro-apoptotic CER[NS] species to sphingosine (C18S) and sphingosine 1-phosphate (C18S1P), with roles in cell survival, degrades ceramides through reversible reactions. CER[NS] are also reversibly converted to sphingomyelin (SM) or further metabolised to ceramide 1-phosphate [C1P]). In a similar way, addition of alpha-hydroxy fatty acids to C18DS, results in CER[ADS] species.

Measured lipid species are in bold; genes encoding enzymes are in italics; genes identified through SNPs that associated at GWAS with circulating lipid levels are in red.

Figure 2: Heritability estimates of N-acyl ethanolamines and ceramides found in human plasma.
This figure depicts the heritability estimated for each lipid species using SNP-based GCTA software (y-axis) and reported pedigree-based QTDT software (x-axis). This data is presented in detail in Table S5.

Figure 3: Family-based GWAS results for N-acyl ethanolamines and the lead SNP in fatty acid amide hydrolase (FAAH).
The radar plot depicts the P-value for association between the lead SNP and eQTL of FAAH (rs324420) and each NAE species. The P-values were grouped into “<5x10^{-8}” (P<5x10^{-8}, outermost ring), “x10^{-6}” (P=5.0x10^{-8} - 9.9x10^{-6} [of which there are no NAE species]), “x10^{-5}” (1.0x10^{-5} - 9.9x10^{-5}), and “NS” (not significant) at the center of the radar.

Figure 4: LocusZoom plot of the association of PEA with FAAH SNP rs324420
The LocusZoom plot depicts the association of N-acyl ethanolamine lipid species PEA with FAAH SNP rs324420 on chromosome 1. The r^2 for each SNP is depicted in colour. The plot was created using the LocusZoom plot tools at http://locuszoom.sph.umich.edu/.

Figure 5: Family-based GWAS results for CER[NS] and precursor CER[NDS] with an exemplar SNP in serine palmitoyltransferase (SPTLC3).
The radar plot depicts the P-value for association between the lead SNP and liver eQTL of SPTLC3 (rs680379) with CER species. The P-values were grouped into “<5x10^{-8}” (P<5x10^{-8}, outermost ring), “x10^{-6}” (P=5.0x10^{-8} - 9.9x10^{-6}, “x10^{-5}” (1.0x10^{-5} - 9.9x10^{-5}), and “NS” (not significant) at the center of the radar.

Figure 6: LocusZoom plot of the association of CER[N(24)S(19)] with SPTLC3 SNP rs680379
The LocusZoom plot depicts the association of CER[N(24)S(19)] with FAAH SNP rs680379 on chromosome 1. While there is a group of lead SNPs, this SNP was depicted as it has been identified previously to associate at GWAS with sphingolipid species. The r^2 for each SNP is depicted in colour. The plot was created using the LocusZoom plot tools at http://locuszoom.sph.umich.edu/.
Table 1: Summary statistics for the study participants.
Data is shown as mean and standard deviation (SD) unless otherwise indicated; BMI, body mass index; WHR, waist-hip ratio.

| Trait                  | Mean (SD)         |
|------------------------|-------------------|
| Gender                 | 47% Male          |
| Hypertensive           | 33%               |
| Mean Blood Pressure    | 138/83 mmHg       |
| Age (years)            | 49 (15)           |
| BMI                    | 26.04 (4.33)      |
| WHR                    | 0.86 (0.09)       |
| Cholesterol (mmol/L)   | 5.61 (1.20)       |
A

NAPE

1. NAPE-PLD
2. PLC, PTPN22
3. ABHD4, GDE1
4. PLD, GDE4, GDE7

NAE

AEA, PEA, OEA, DHEA, SEA, VEA, HEA, LEA, DPEA, POEA, PDEA

FAAH

Fatty acid + Ethanolamine

B

Palmitoyl-CoA + L-serine

SPTLC 1-3

3-keto dihydrosphingosine

C18DS → CER[ADS] → CER[AS]

CERS

CER[NDS]

DEGS1

C18S → C18S1P

SGPP 1-2

C1P

SM
